The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: A randomized controlled trial

Cardiology (Switzerland)

Volumn 125, Issue 4, 2013, Pages 235-241

  Yang, Longquan ^a   Yu, Jing ^a   Ma, Ruixin ^a   Zhao, Feng ^a   Lin, Xin ^a   Liu, Peijun ^a   Hu, Hao ^a   Bai, Feng ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Combination therapy; Felodipine; Hypertension; Oxidative stress; Sexual function

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; FELODIPINE; IRBESARTAN; MALONALDEHYDE; METOPROLOL; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL;

EID: 84879467200     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000350955     Document Type: Article

References (33)

1. Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB: Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003; 61: 201-206.
2. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB: Sexual function in men older than 50 years of age: results from the health professionals followup study. Ann Intern Med 2003; 139: 161-168.
3. Akkus E, Kadioglu A, Esen A, Doran S, Ergen A, Anafarta K, Hattat H: Prevalence and correlates of erectile dysfunction in Turkey: a population-based study. Eur Urol 2002; 41: 298-304.
4. Mak R, De Backer G, Kornitzer M, De Meyer JM: Prevalence and correlates of erectile dysfunction in a population-based study in Belgium. Eur Urol 2002; 41: 132-138.
5. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R: Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569-574, discussion 574-575.
6. Mirone V, Ricci E, Gentile V, Basile Fasolo C, Parazzini F: Determinants of erectile dysfunction risk in a large series of Italian men attending andrology clinics. Eur Urol 2004; 45: 87-91.
7. Jin L, Lagoda G, Leite R, Webb RC, Burnett AL: NADPH oxidase activation: a mechanism of hypertension-associated erectile dysfunction. J Sex Med 2008; 5: 544-551.
8. Koupparis A, Jeremy JY, Persad R, Angelini GD, Shukla N: Smoking and erectile dysfunction: the role of NADPH oxidase. BJU Int 2004; 94: 257-258.
9. Musicki B, Liu T, Lagoda GA, Strong TD, Sezen SF, Johnson JM, Burnett AL: Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. J Sex Med 2010; 7: 3023-3032.
10. Ding Y, Gonick HC, Vaziri ND, Liang K, Wei L: Lead-induced hypertension. 3. Increased hydroxyl radical production. Am J Hypertens 2001; 14: 169-173.
11. Vaziri ND, Wang XQ, Oveisi F, Rad B: Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000; 36: 142-146.
12. Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, Tsiodras S, Dimitriou D, Giamarellou H: Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J Androl 2006; 27: 469-477.
13. Cordero A, Bertomeu-Martinez V, Mazon P, Facila L, Bertomeu-Gonzalez V, Conthe P, Gonzalez-Juanatey JR: Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther 2010; 28: 15-22.
14. Dusing R: Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29-34.
15. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P: Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11: 1244-1247.
16. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L: Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27-31.
17. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, Argaya Roca M, Pol Bravo C, Sanchez Zamorano MA, Ferrario CM: Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336-341.
18. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH: Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34: 327-331.
19. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.
20. Au WW, Oberheitmann B, Harms C: Assessing DNA damage and health risk using biomarkers. Mutat Res 2002; 509: 153-163.
21. Colwell BA, Morris DL Jr: Formation of the oxidative damage marker 8-hydroxy-2′ -deoxyguanosine from the nucleoside 2′ -deoxyguanosine: parameter studies and evidence of Fe(II) binding. J Inorg Biochem 2003; 94: 100-105.
22. Draper HH, Hadley M: Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990; 186: 421-431.
23. Poli G, Schaur RJ, Siems WG, Leonarduzzi G: 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev 2008; 28: 569-631.
24. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
25. Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, Tsiodras S, Dimitriou D, Giamarellou H: Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl 2006; 8: 177-182.
26. Baumhakel M, Schlimmer N, Bohm M: Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008; 20: 493-500.
27. Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S: Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010; 121: 1439-1446.
28. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, Mugellini A: Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177-180.
29. Dincer Y, Sekercioglu N, Pekpak M, Gunes KN, Akcay T: Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease. Ren Fail 2008; 30: 1006-1011.
30. Luchtefeld M, Bandlow N, Tietge UJ, Grote K, Pfeilschifter J, Kaszkin M, Beck S, Drexler H, Schieffer B: Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation. Atherosclerosis 2007; 194: 62-70.
31. Cicek D, Tamer L, Pekdemir H, Cin VG, Yildirim H, Kara AA, Yurtdas M: Coronary angioplasty induced oxidative stress and its relation with metoprolol use and plasma homocysteine levels. Anadolu Kardiyol Derg 2006; 6: 308-313.
32. Kopff M, Kowalczyk E, Kopff A: Influence of selected cardiological drugs on oxidative status. Pol J Pharmacol 2004; 56: 265-269.
33. Ma R, Yu J, Xu D, Yang L, Lin X, Zhao F, Bai F: Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens 2012; 30: 210-216.